Patents by Inventor Dale J. Kempf

Dale J. Kempf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of filarial diseases
    Patent number: 10238677
    Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: March 26, 2019
    Assignees: LIVERPOOL SCHOOL OF TROPICAL MEDICINE, ABBVIE INC.
    Inventors: Thomas W. Von Geldern, Dale J. Kempf, Kennan C. Marsh, Mark John Taylor, Stephen Andrew Ward, Louise Ford, Joseph Turner
  • Tylosin A analogs and derivatives
    Patent number: 10072040
    Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 11, 2018
    Assignee: ABBVIE INC.
    Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
  • TREATMENT OF FILARIAL DISEASES
    Publication number: 20170368088
    Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 28, 2017
    Applicants: AbbVie Inc., Liverpool School of Tropical Medicine
    Inventors: Thomas W. VON GELDERN, Dale J. KEMPF, Kennan C. MARSH, Mark John TAYLOR, Stephen Andrew WARD, Louis FORD, Joseph TURNER
  • TYLOSIN A ANALOGS AND DERIVATIVES
    Publication number: 20160200757
    Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.
    Type: Application
    Filed: March 9, 2016
    Publication date: July 14, 2016
    Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 9309279
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: April 12, 2016
    Assignees: AbbVie Inc., Enanta Pharmaceuticals, Inc.
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Kenneth Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
  • TYLOSIN A ANALOGS AND DERIVATIVES
    Publication number: 20150259374
    Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 17, 2015
    Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
  • Compositions and methods of use of ritonavir for treating HCV
    Patent number: 8901157
    Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: December 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Dale J. Kempf, Kennan C. Marsh
  • CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140243340
    Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: AbbVie Inc.
    Inventors: Larry L. Klein, Hui-Ju CHEN, Ming C. YEUNG, Charles A. Flentge, John T. Randolph, Peggy Huang, Douglas K. Hutchinson, Dale J. Kempf
  • HIV Protease Inhibiting Compounds
    Publication number: 20140194349
    Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicant: AbbVie Inc.
    Inventors: David A. DeGoey, Charles A. Flentge, William J. Flosi, David J. Grampovnik, Dale J. Kempf, Larry L. Klein, Ming C. Yeung, John T. Randolph, Xiu C. Wang, Su Yu
  • Compounds that are useful for improving pharmacokinetics
    Patent number: 8741938
    Abstract: Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: June 3, 2014
    Assignee: AbbVie Inc.
    Inventors: Dale J. Kempf, Charles A. Flentge, John T. Randolph, Peggy Huang, Larry L. Klein
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20140148573
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicants: Enanta Pharmaceuticals, Inc., AbbVie, Inc.
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Kenneth Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
  • HIV protease inhibiting compounds
    Patent number: 8653141
    Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: February 18, 2014
    Assignee: AbbVie Inc.
    Inventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8642538
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: February 4, 2014
    Assignee: AbbVie, Inc.
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik
  • NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS
    Publication number: 20130317071
    Abstract: Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 28, 2013
    Inventors: Dale J. Kempf, Charles A. Flentge, John T. Randolph, Peggy Huang, Larry L. Klein
  • Compounds that are useful for improving pharmacokinetics
    Patent number: 8524753
    Abstract: Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: September 3, 2013
    Assignee: AbbVie Inc.
    Inventors: Dale J. Kempf, Charles A. Flentge, John T. Randolph, Peggy Huang, Larry L. Klein
  • CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130131085
    Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
    Type: Application
    Filed: December 13, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Larry L. Klein, Hui-Ju Chen, Ming C. Yeung, Charles A. Flentge, John T. Randolph, Peggy P. Huang, Douglas K. Hutchinson, Dale J. Kempf
  • Prodrugs of HIV protease inhibitors
    Patent number: 8426388
    Abstract: A compound of the formula is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions for inhibiting HIV protease activity and treating HIV infection are also disclosed.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: April 23, 2013
    Assignee: AbbVie Inc.
    Inventors: David A. DeGoey, William J. Flosi, David J. Grampovnik, Larry L. Klein, Dale J. Kempf, Xiu C. Wang
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8420596
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: April 16, 2013
    Assignees: Abbott Laboratories, Enanta Pharmaceuticals, Inc.
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik
  • HIV PROTEASE INHIBITING COMPOUNDS
    Publication number: 20130023463
    Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
    Type: Application
    Filed: April 19, 2012
    Publication date: January 24, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
  • Anti-viral compounds
    Patent number: 8338605
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: December 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V. L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu